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“Om snöret inte håller, utan går av, är det bara att försöka med ett annat snöre.” 
 
Nalle Puh  (A.A Milne)

  
ABSTRACT 
Propofol is one of the most used intravenous anaesthetics in the western world. It is often 
used for ambulatory surgery due to favourable pharmacokinetic properties allowing quick 
onset and short emergence time. However, there is considerable interindividual variation in 
pharmacokinetics and dynamics as well as gender differences. Differences in metabolism due 
to polymorphic enzymes may be a contributing factor to this variation. To enable early and 
smooth discharge from hospital after ambulatory surgery, a quick postoperative cognitive 
recovery is essential. It is not known whether the great variation in propofol 
pharmacokinetics and pharmacodynamics affect the cognitive recovery of the ambulatory 
patient receiving propofol.  
By studying correlation between genotype and propofol metabolite production both in liver 
microsomes and in humans after propofol anaesthesia, we aimed to further describe the 
variations in propofol pharmacokinetics. Postoperative cognitive recovery in women 
undergoing ambulatory breast cancer surgery with propofol or desflurane anaesthesia was 
studied, using the PQRS and CFQ as assessment tools. Further the cognitive performance 
according to PQRS in a test re-test situation in pre-surgery cancer patients compared to 
controls was evaluated. 
Our results demonstrate a great variation in production of propofol metabolites in vitro and in 
vivo, but no correlation between metabolite level and genotype. Females showed a higher 
propofol metabolite level compared to men after both bolus dose and infusion of propofol.        
Cognitive recovery was similar after propofol and desflurane anaesthesia, and subjectively 
not complete one week after surgery. We found that pre-surgery cancer patients expressed a 
higher level of anxiety and had lower cognitive baseline test performance compared to 
controls, resulting in a high exclusion rate in the patient group. The groups had a similar re-
test performance in the PQRS cognitive domain. 
In conclusion, we found a considerable variability in production of propofol metabolites but 
no correlation to genotype. There was an increased production of propofol metabolites in 
women compared to men. The protracted postoperative cognitive recovery assessed by PQRS 
and CFQ after ambulatory surgery was similar after propofol and desflurane anaesthesia, 
suggesting that possible remains of propofol or its metabolites do not affect cognitive 
performance more than residual effects of desflurane. When assessing postoperative 
cognitive recovery it should be acknowledged that the anxiety and stress caused by a severe 
disease and wait for surgery may have an impact on cognitive PQRS test performance. The 
use of the revised PQRS cognitive scoring system may lead to the exclusion of a considerable 
part of the patients due to too low baseline performance. 
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INTRODUCTION 
We are all different.  
 
The hospital was big, white, shiny and newly built. Minna and Hedda, two young women 
unknown to each other, were sharing a room. Beforehand they had both been promised their 
own spacious room with a beautiful view over the city, but unfortunately, the ward was out of 
single rooms, too many patients had been admitted to the hospital in the past few days as a 
result of the sudden black ice that had struck the city. Both Minna and Hedda were victims of 
the black ice, they had broken bones and they were waiting for surgery the following day. 
Minna was not really interested in talking to anyone, but her new roommate Hedda was an 
energic talkative person. 
“Have you had surgery before?” Hedda asked, lots of excitement in her voice, and without 
waiting for an answer she continued:                                                                                         
“I haven’t but I have heard from friends that getting anaesthesia is one of the best things 
they’ve ever had. It’s like having a really great dream. And afterwards you´re just happy.  
And get snacks and drinks at the postoperative ward. And then you go home and get to stay at 
home for a couple of days even though you feel fine, some extra days off from work for free. I 
have lots to do at home, the timing of my broken leg is perfect.” 
Minna turned to her roommate. 
“I haven’t had surgery before, but all my friends who have had surgery have felt terrible 
afterwards, throwing up for days and not been able to get out of bed for a week. To conclude, 
I am not looking forward to tomorrow.” 
Hedda stared at Minna for a short while, shrugged her shoulders and went back to the book 
she was reading. 
Shortly after, the surgon, Dr Johanna, was entering the room. 
“Good evening, hope you feel alright. Tomorrow at this time you will be newly operated and 
happy, any questions?” Before Minna and Hedda had time to open their mouths, Dr 
Johannas’ phone rang, she went out to take the call and didn’t come back. 
Minna spent the rest of the evening trying to solve the crossword from “Svenska Dagbladet”, 
but she was unable to concentrate, all her thoughts were mixed up and the focus all gone. She 
couldn’t get rid of the nagging unease she felt when thinking about tomorrow’s anaesthesia 
and surgery.  
The following day Minna and Hedda were transported to the operating ward. In the 
operating room, before anaesthesia was started, the anaesthetist asked a few questions about 
general health, former surgery, if they were ever sea sick, had any allergies and so on. 
“Everything is perfect!” the anaesthetist said, “now just breathe deeply in this mask and you 
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will soon fall asleep.” They were both given the standard doses of the intravenous 
anaesthetic propofol. “It´s an amazing drug”, the anaesthetist thought by herself,” I just give 
2.5 mg/kg of this terrific whitish liquid, my patient falls asleep, the infusion goes on during 
the surgery, I switch it off when surgery is over and my patient wakes up. I can just sit and 
watch and have my coffee. I have a wonderful job”.  Minna and Hedda went through 
identical surgery. The length of surgery was the same and since they were of the same size 
they got about the same dose of painkillers at the end of the surgery, morphine and 
paracetamol, as usual. The anaesthesia and surgery was uneventful with no complications. 
However, the schedule of the day was a little bit delayed due to the fact that it took more than 
30 minutes to get Hedda to wake up. A little bit irritating the anaesthetist thought.  
Minna opened her eyes on the postoperative ward. She felt rested. She was hungry and thirsty 
and immediately felt like stretching her limbs, sitting up and maybe trying to walk a few 
steps. She hardly had any pain at all. In the bed next to her she heard a familiar voice, 
Hedda. Hedda was spluttering when she was talking, but Minna could still hear that she was 
complaining about nausea. And pain.  
A few hours later, Minna went back to the ward where she had a shower and read 
yesterday’s newspaper. She had a glimpse at the crossword again and was a little surprised;  
How could I not finish this off yesterday, it is simple, she thought for herself and filled in all 
the missing words in a few minutes. 
 Next she had a surprisingly well tasty dinner. They really had improved the food at the new 
hospital. In the evening, she spoke to Dr Johanna, who was very content with the operation. 
Minna asked where her roommate was and Dr Johanna chuckled; 
“I guess she was a little bit weaker than you, she stayed on the postop ward over night!” 
Hedda didn’t showed up until lunchtime the next day. Minna had packed her belongings and 
was just about to leave the room and the hospital when Hedda came back from the 
postoperative ward. She looked pale and sick. 
“Eh, hi. I am just leaving. If you haven’t had lunch I can really recommend the smoked 
salomon, it’s great!” Minna said. 
Hedda lifted the plastic bag from her lap to her face. Minna plugged the headphones into her 
ears, increased the volume of the music and left the room. Finally Hedda got her own 
spacious room in the new hospital. That was a good thing since she had to stay for another 
three days due to nausea and dizziness. Had she been able to eat and walk she would have 
been impressed by the quality of food and the beautiful city view. 
 
Minna and Hedda are both young women with the same ethnic origin. They have similar 
injuries and are undergoing similar operations. They are healthy and do not take any 
medication. In the hospital, they get similar treatment and the same drugs in similar doses. 
The length of their operations is about the same. Still their recoveries after surgery and 
anaesthesia are completely different – Minna who was worried and maybe even a little 
  3 
cognitively affected the day before the surgery, is feeling well at once and can leave the 
hospital the following day while Hedda has to stay for several days.   
This happens every day in the hospital – the recovery and resumption of mental and physical 
capacities after surgery and anaesthesia vary considerably between individuals. Often we 
don’t know why. There are several factors that may cause variations in postoperative 
recovery, i.e. co-morbidity1 age, gender2,3, type and length of surgery and anaesthesia1,4, 
pain5, nausea6, genetics7,8.  
There are remains of anaesthetics in the body for hours to days after administration9,10. The 
clearance of drugs depends on their distribution, metabolism and elimination. Most drugs are 
metabolized and eliminated mainly as inactive metabolites. The halogenated inhaled 
anaesthetics are eliminated as intact active molecules washed out by exhalation, while the 
anaesthetics administered by the intravenous route are usually dependent on liver metabolism 
for the elimination and subsequent cessation of effect. There may also be some 
neurochemical residual central nervous system (CNS) effects. 
Propofol is one of the most used intravenous anaesthetics in the western world. Due to its 
pharmacokinetic properties resulting in quick onset and short emergence time it is a suitable 
drug for ambulatory as well as prolonged surgery. However, there are great interindividual 
differences in propofol pharmacokinetics and pharmacodynamics, and the reasons for this are 
not fully clarified11,12. Propofol is metabolised by highly polymorphic enzymes, which means 
there are more or less efficient variants in the population.  
It is not known if a variation in the efficiency of these enzymes has a clinical 
significance. Variability in enzyme capacity may alter the metabolism of propofol, in 
some cases slow elimination and possibly prolong recovery or increase side effects. 
Ambulatory surgery is increasing, and with that the patient´s length of stay in the hospital is 
shortened. Many patients are expected to return home the same day or the day after surgery, 
which requires a quick recovery with a minimum of complications. Cognitive recovery is an 
important part of the recovery process, during which the patient regains his/her memory, 
verbal ability, perception, attention, executive function and abstract thinking. It is believed 
that cognitive impairment observed during the first postoperative week is possibly associated 
with residual effects of anaesthetics and/or analgesic drugs13-15.  
It is not known whether interindividual differences in metabolic capacity of propofol 
contribute to variations in cognitive recovery. 
The focus of the present thesis was the impact of genetic variability on the metabolism of 
propofol, and the variation in cognitive recovery after ambulatory anaesthesia with propofol, 
using the least soluble and most inert inhaled anaesthetic desflurane as control. Also the 
impact of preoperative stress on the cognitive test performance in patients waiting for cancer 
surgery was investigated. 
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PROPOFOL 
In general 
Propofol (2,6-diisopropylphenol) is an alkyl phenol which was developed in the 1970’s and 
first described as a potential anaesthetic agent by Kay et al in 197716. It has been used in 
Sweden since 1987 and is today one of our most commonly used intravenous anaesthetics. 
Propofol has favourable properties such as quick onset and quick emergence in combination 
with low toxicity and relatively few side effects, which makes it a suitable drug both for 
sedation and anaesthesia. 
Propofol is mostly found to be comparable to inhaled anaesthetics with respect to time to 
discharge from the hospital, and often considered to decrease the occurrence of PostOperative 
Nausea and Vomiting (PONV)6,17,18. The recovery assessment after propofol anaesthesia has 
frequently focused on the early part of the recovery process, emergence from anaesthesia, 
resumption of stable vital functions and protective reflexes and further logistic factors such as 
“eligible for discharge” which involves regaining physical abilities such as standing, walking, 
and eating in order to be home ready. The more protracted recovery process after propofol 
anaesthesia such as resumption of cognitive capacity and becoming “street-fit” is less well 
defined6,17.  
Pharmacokinetics and pharmacodynamics  
Propofol is highly lipophilic, which results in a rapid crossing of the blood-brain barrier, 
reaching the effect site and leading to a quick onset. The effect duration is short due to as 
quick redistribution from the brain to surrounding tissues. The pharmacokinetics are 
described as three compartmental; initial distribution into the central compartment, further 
rapid redistribution into both well and less well perfused compartments with slow 
redistribution back into the central compartment to be metabolised19-21. The slow 
redistribution in combination with quick metabolism adds to the quick emergence. The 
plasma concentration profile following a bolus dose is described in figure 1.  The distribution 
half-life after bolus is approximately 2-4 minutes, and the volume of distribution (Vd) has 
been found to vary between 209-1008 l22. Clearance depends on whether bolus or infusion is 
given and varies between 77-139 l/min21. Context sensitive half-life up to eight hours is less 
than 40 minutes23.  
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Fig. 1 The figure demonstrates the propofol concentration in plasma after bolus dose in healthy volunteers. 
The initial high peak concentration after injection decreases as propofol quickly redistributes into peripheral 
compartments, thereafter follows a slow decrease in plasma concentration, as propofol redistributes back into 
the central compartment and is metabolised. Masui et al 201024  
Propofol is metabolised by enzymes, mainly in the liver, and metabolism is almost 
complete, leaving less than 1 % of the drug to be excreted unchanged in the urine10. During 
anhepatic surgery such as liver transplantation, there has been evidence of extrahepatic 
metabolism, which is most likely taking place in the kidney25 26 27 28. Metabolic capacity is 
dependent not only on the enzymatic capacity but also on the liver blood flow and 
oxygenation. Thus, metabolism may be influenced by circulatory changes caused by 
anaesthesia itself and also by surgery29-31. Propofol has a high level of protein binding (96-
99%) to serum albumin32. 
The metabolism of propofol follows two main routes; direct glucuronidation forming 
propofolglucuronide (PG) or by hydroxylation to form quinol (Q). Quinol is further 
conjugated with glucuronic acid or sulphatic acid to form quinol-1-glucuronide (1-QG) and 
quinol-4-glucuronide (4-QG), or quinol-4-sulphate (4-QS)9,33. The water soluble PG, 1-QG, 
4-QG and 4-QS are excreted in the urine (Figure 2). PG is considered to be the main 
metabolite even though there is a great interindividual variation (10-67%)9,10,33,34.  
max.%plasma%concentra/on%
quick%redistribu/on%
to%peripheral%
compartments%
slow%redistribu/on%
back%to%the%central%
compartment,%
metabolism%
bolus%dose%
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Fig.2 The figure illustrates the metabolic pathway of propofol through hydroxylation by CYP2B6 or 
glucuronidation by UGT1A9. The percentage stated below the respective enzyme illustrates the variation in 
metabolic pathway between individuals observed in several studies10,34. 
Propofol metabolites are found to remain for a long time in the body. Favetta et al. found 
that only 38 % of the drug had been excreted in the urine 24 hours after a bolus dose, and 
60 hours after a 4 hour propofol infusion, the excretion in the urine was still not complete 
(30-94 %)10,34. The excerted metabolites glucuronides and sulphates, are pharmacologically 
inactive but quinol is thought to have one third of the clinical effect of propofol35. Thus, 
trace concentrations of quinol may possess pharmacological a residual effect.   
Propofol is known to have brochodilatating properties36,37, be anticonvulsive38 and decrease 
intracerebral bloodflow and  intracranial pressure39,40. Propofol possesses anti-inflammatory 
activity41 and have shown antioxidative effects42,43. It also has antiemetic properties6 17. The 
side effects are few and relatively mild. Propofol decreases blood pressure44 due to 
decreased sympaticus tonus, but cardiac inotropy is unchanged with therapeutic doses45. As 
for other intravenous anaesthetics transient apnea after induction is common46,47.  
Propofol main site of action is through stimulation of the postsynaptic inhibitory γ-
aminobutyric acid (GABA) receptor GABAA and thereby increasing transmission48,49. Other 
sites of action discussed are the depressive effect on the excitatory N-Methyl 1-D-Aspartate 
(NMDA) receptor40 and also stimulation of the inhibitory glycine recptor50.  
A rare but fatal complication of propofol administration is ”propofol infusion syndrome”, 
which has mostly affected pediatric and adolescent patients who have received the drug in 
high dose for many days. The syndrome seems to be caused by impaired mitochondrial 
respiration which in turn results in critical rhabdomyolysis, metabolic acidocis and 
hemodynamic collapse23. 
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Genetics 
The enzymes responsible for the biotransformation of propofol to its metabolites are mainly 
uridine diphosphate (UDP) glucuronosyltransferase 1A9 (UGT1A9) and cytochrome P450 
2B6 (CYP2B6)35,51. Both UGT1A9 and CYP2B6 are highly polymorphic which means they 
exist in many variants in the population. Polymorphism may give rise to more or less efficient 
gene products, in this case more or less efficient enzymes, and this in turn may affect the 
efficiency of the metabolism52. It is believed that polymorphism in commonly drug 
metabolising enzymes may be a considerable reason for over- and under-treatment of many 
patients which in turn leads to an increased frequency of adverse effects, prolonged stay in 
hospital or a lack of effect53. 
UGT1A9 and CYP2B6 metabolism of propofol has shown to vary extensively between 
individuals10 34,35. So far, 38 alleles (variants of the same gene) of CYP2B6 have been found 
(www.cypalleles.ki.se). In vivo studies have shown increased activity for the allele 
CYP2B6*4 and decreased activity for the allele CYP2B6*654,55. As for UGT1A9, 27 alleles 
are registered (www.ugtalleles.ulaval.ca). UGT1A9 M33T (*3) has demonstrated reduced 
propofol glucoronidation activity, while UGT1A9 with a mutation in the 275A/-2152T 
regions has been identified with increased propofol glucuronidation activity56. The frequency 
of the mutations varies in between ethnical groups, which is of importance for the possible 
clinical impact of the polymorphism in various populations57,58.  
DESFLURANE 
Desflurane belongs to the third generation of halogenated inhaled anaesthetics together with 
sevoflurane. Desflurane is the halogenated inhaled anaesthetic with the lowest blood and fat 
solubility and thus the most favourable, rapid pharmacokinetics. The blood gas coefficient of 
about 0,42 promotes quick equilibration during induction, and the low fat, tissue and blood 
solubility is associated with a rapid elimination after cessation of administration. Desflurane 
undergoes a minimum of metabolism and thus elimination is solely dependent on exhalation 
at end of anaesthesia. When compared to other anaesthestics, desflurane has shown to result 
in the quickest emergence recovery6,59,60. Desflurane may thus be seen as the anaesthetic with 
the least variability in kinetics. 
ANAESTHESTICS AND GENDER 
Men and women are physiologically and pharmacologically different in numerous ways 
which affect the response to drug treatment. Physiological differences such as body 
constitution leading to different volume of distribution2, hormonal variations affecting 
bioavailability61, level of protein binding as well as cardiovascular62 and respiratory 
function63 are described. For some drugs the pharmacokinetics differs up to 40 % in 
between men and women64. Gender differences in drug metabolism is believed to be one of 
the main reasons behind the divergent drug reponse65. An increased activity for CYP3A4 is 
reported for women66, and studies of human liver tissues have shown that women tend to 
express higher levels of CYP2B6 in liver than men67. However, Ilic et al. did not observe 
any gender difference in in vivo CYP2B6 activity correlated to metabolism68. As for 
anaesthetic drugs, women are more sensitive than men to the water soluble neuromuscular 
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relaxants due to smaller volume of distribution and thereby higher concentration in plasma2. 
Women are also found to be more sensitive to opioids than men69. Considering the many 
differences in drug response reported, it is plausible that gender difference in response to 
anaesthetics varies in many other ways than the above mentioned70. Female gender is a risk 
factor of PONV71,72 and sex hormones are believed to be contributory to this difference71-74.  
Propofol and gender 
Women have a higher volume of distribution of propofol and also a higher clearance than 
men75, and they need a higher dose in order to maintain a preset depth of anaesthesia 
according to Bispectral Index (BIS) electro encephalography (EEG) analysis76. Women also 
seem to undergo a more rapid decline in propofol concentration77 and wake up faster than 
men 3,12,78-80. In one study, men were more easily sedated than women81. Results on gender 
difference in central sensitivity to propofol are contradictory76,77.  
POSTOPERATIVE RECOVERY 
The postoperative recovery is a continuous process starting from the end of anaesthesia and 
ending when the patient has returned to his or her full preoperative status. According to the 
society of ambulatory surgery, recovery can be categorized into three parts; early recovery 
which is the period from the end of anaesthesia until the patient regains basal protective 
reflexes and motor movements, intermediate recovery during which the patient gets ready for 
discharge from the hospital, and late recovery, a period when the patient returns to the 
preoperative status. Previously, recovery was measured by postoperative morbidity and 
mortality. Today, both morbidity and mortality are relatively rare side effects of ambulatory 
surgery and anaesthesia, and the assessment of recovery is increasingly focusing on 
resumption of preoperative capacities, ability to cope with basic functions and patient´s 
satisfaction. The “quality of recovery” is frequently assessed, meaning the patient’s 
subjective view of recovery.   
Multiple factors affect recovery, PONV being the side effect most frequently resulting in 
readmittance to hospital82. Postoperative pain is also a common side effect which may 
prolong hospital stay83. Other pre- and postoperative factors that should be taken into 
consideration influencing postpoperative recovery are co-morbidity, age84, but also 
preoperative anxiety and sleep deprivation85, the last two affecting in particular the cognitive 
recovery of the patient. Mild residual cognitive effects are not uncommonly experienced 
during the intermediate postoperative course86,87. Both long-term and short-term cognitive 
dysfunction are commonly seen after surgery and anaesthesia4,88. 
Neurocognitive side effects 
Neurocognitive side effects following surgery and anaesthesia have been observed and 
studied for many years, initially in patients undergoing cardiac surgery89, but also after non-
cardiac surgery88. Old age4,90, low level of education90, co-morbidity4 and increased length of 
surgery and anaesthesia1,91 are some of the risk factors associated to the development of 
postoperative cognitive impairment. There are various types of neurocognitive side effects; 
emergence agitation, emergence delirium, Postoperative Delirium (PD) and the more long 
lasting PostOperative Cognitive Dysfunction (POCD). Emergence agitation is usually seen 
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within hours92 and PD 24 – 72 hours after end of surgery and anaesthesia93. The focus of 
postoperative cognitive research has mainly been on POCD, a state that refers to a prolonged 
postoperative change in cognition emerging after the first postoperative week and tested by 
extensive and sophisticated neuropsychological tests94. The test battery developed by the 
International Study on PostOperative Cognitive Dysfunction (ISPOCD)90 is the gold 
standard, but since a definition of POCD is lacking and the design and cognitive tests used 
within the studies is varying, the results are difficult to compare95. 
Neuroinflammation as a stress response to surgery and anaesthesia is the mechanism 
believed to be involved in the development of postoperative cognitive impairment96. 
Whether neuroinflammation is involved in both short-term transient cognitive impairment 
and long-term cognitive dysfunction is not known. Jildenstal et al. found that less deep 
anaesthesia titrated by Auditory Evoked Potential Index (AAI) was associated with lower 
levels of the inflammatory interleukin IL-6 and less cognitive impairment in the first 24 
hours but not one week postoperatively97, which could indicate that an inflammatory 
process is being responsible for short-term cognitive impairment as well.  
Postoperative recovery and anaesthesia 
Anaesthesia is a pharmacological dose-dependent depression of the CNS. Awakening and 
CNS recovery take place after cessation of drug administration and is related to the 
elimination of anaesthetics and residual pharmacodynamic effects. It is difficult to 
differentiate between the natural cognitive recovery following surgery and anaesthesia and 
a possible mild neuro-inflammatory insult. Difficulty in the ability to concentrate during the 
first postoperative hours to days5 98, and transitory residual cognitive decline resolving 
during the postoperative first week is commonly reported99. Most clinical studies on 
postoperative cognitive impairment are conducted from one week postoperatively, and 
focus on the development of POCD. There is no consensus on when postoperative 
cognitive impairment is really POCD, but in a review by Newman et al., all POCD-studies 
with neuropsychological assessments within one week after surgery were excluded in order 
”to avoid the general effects of any anaesthetic agent”88, and in several studies it is 
suggested that the cognitive impairment within a week after surgery and anaesthesia is 
caused by remaining anaesthetic and analgesic drug effect rather than a pathological 
structural change in the CNS13-15. Royse et al. compared cognitive recovery after propofol 
or desflurane anaesthesia in patients undergoing coronary artery bypass, and found a worse 
cognitive recovery in the propofol group at day 3-7 postoperatively but no difference at 
three months postoperatively100. It is from those results not possible to assess whether these 
differences were caused by remains of anaesthetics or remaining effects on the CNS by 
anaesthetics or by a systemic stress response including neuro-inflammation. 
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Fig. 3 The figure demonstrates when the postoperative cognitive recovery and pathological neurocognitive 
side-effects after surgery and anaesthesia usually occur. Emergence delirium and agitation and postoperative 
delirium normally cease within one week postoperatively. POCD, PostOperative Cognitive Dysfunction is 
believed to develop from one week postoperatively and onwards. Recovery of cognitive perfomance back to 
preoperative status is expected to start immediately postoperatively.  
Postoperative cognitive recovery and regional vs. general anaesthesia 
Anaesthesia has its site of action in the brain and it is known to affect memory and 
learning101,102. It is possible that remaining impact of anaesthetics cause transient 
postoperative cognitive effects in patients. This is strengthened by the fact that general as 
opposed to regional anaesthesia is associated with a greater risk of short term cognitive  
dysfunction13-15. Local and regional anaesthesia is associated with a more favourable early 
and intermediate recovery103-106.   
Several studies demonstrate better cognitive performance day 1 – 3 after surgery among 
patients who received regional vs. general anaesthesia107,108. However, there is still no clear 
evidence to show whether there is a difference in the risk for neurocognitive side effects 
between general and regional anaesthesia13,109. A meta-analysis from 2010 concluded that it 
appears that general anaesthesia, compared to others, may increase the risk of 
developing POCD; however this has not been shown for PD110. The impact of depth of 
anaesthesia on postoperative cognitive impairment is controversial with opposing results111-
113. 
Postoperative cognitive recovery and choise of general anaesthetic 
Early cognitive recovery with respect to different anaesthetic regimens has been studied, 
but cognitive test methods, type of surgery and anaesthetic care all vary. Larsen et al. found 
that anaesthesia with propofol and remifentanil resulted in a quicker cognitive recovery 
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than desflurane or sevoflurane114, but Biedler et al. using a more complex cognitive test 
battery, found the opposite115. Moore et al found no difference in 4 different anaesthetic 
regimens when asking for ”forgetfulness” and problems to concentrate up to one week 
postoperatively98. Cognitive dysfunction was as high as 46 % 24 hours postoperatively in 
an group of elderly patients undergoing general surgery, no difference between sevoflurane 
and propofol anaesthesia was seen116. Parida et al. observed that early cognitive function 
was slightly quicker after sevoflurane compared to propofol117, but that home readiness was 
similar between groups.  
Assessment of Postoperative Recovery 
The recovery assessment tool to be used depends on which part of recovery is to be 
evaluated; early, intermediate or late recovery. Former assessment tools have focused on 
just one phase in recovery such as the Aldrete score118 evaluating early recovery and the 
Post-Anaesthetic Discharge Scoring System (PADSS) assessing intermediate recovery119. 
Recently the Postoperative Quality of Recovery Scale (PQRS) was developed, covering all 
three phases of recovery120.   
The assessment of recovery of today is a multidimensional judgement based on various 
parameters such as physiological, cognitive and emotional parameters. Various tools for 
assessment of quality of recovery have been developed and used, which makes comparison 
between studies difficult. In 2000, Herrera et al. found that Quality of Recovery 40 
(QoR40) at that time was the only recovery instrument for ambulatory surgery that fulfilled 
the criteria from a quality point of view. However, this tool was considered to be 
inappropriate for ambulatory surgery121. QoR40 was shortened to develop QoR15 which 
has also been validated122. Both QoR 40 and 15 are tools asking for the patient’s subjective 
view of recovery. The Cognitive Failure Questionnaire (CFQ) is also a patient’s subjective 
assessment tool, purely cognition focused. The CFQ was initially used within the field of 
psychology, but then used to assess postoperative cognitive recovery123,124.                              
Objective assessment of postoperative cognitive recovery 
Cognitive recovery assessment is complex. Quality of recovery tools are important to 
reflect the patient’s view of recovery. However, it has been repeatedly shown that the 
patient’s subjective view of cognitive recovery is usually not consistent with objective 
cognitive recovery. Therefore objective cognitive tests are of great importance125,126. In year 
2010, the Postoperative Quality of Recovery Scale (PQRS) was developed, a 
multidimensional tool involving six domains of importance for recovery (physiological, 
nociceptive, emotive, activities of daily living, cognition and the overall patient 
perspective)120. The scale has been validated for various patient groups and surgical 
interventions86,127, and is intended to be used for both early, intermediate and late recovery 
after surgery and anaesthesia. As opposed to most other recovery scales, which have a 
composite score, the PQRS has dichotomous score for each domain, making it easier to 
identify within which area the patient is recovered or not recovered. Also, the PQRS 
cognitive domain consists of five validated objective neurocognitive tests while most other 
recovery tools assess subjective cognitive recovery128. However, it is stressed that the 
cognitive domain of the PQRS is not to be compared with the more complex 
neurophysiological tests battery intended to diagnose POCD, but instead designed to evaluate 
the patient’s return of cognitive function after surgery and anaesthesia129. 
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In summary, ambulatory surgery and early postoperative discharge from the hospital is 
increasingly adopted. This demands a quick and smooth postoperative recovery. Cognitive 
recovery is an important part of the recovery process, not the least for patients undergoing 
ambulatory surgery. Impaired cognitive recovery within the first week after surgery and 
anaesthesia can be partly caused by remaining trace concentrations of the anaesthetic drug 
and/or its possibly active metabolites, or by residual effects in the CNS per se.  
The postoperative recovery varies a lot in between patients, and the factors behind this are 
not fully clarified. Propofol is often used in ambulatory anaesthesia, due to fast onset and 
short emergence. The pharmacokinetics and pharmacodynamics of propofol vary a lot in 
between individuals and the reasons for this are unknown. Propofol is metabolised by 
polymorphic enzymes, and there are more or less efficient variants in the population. It is 
not known whether this polymorphism has a clinical impact on the metabolism and as a 
result of that on the early as well as the intermediate postoperative cognitive recovery. 
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AIMS 
The overall aim was to study propofol with respect to genetical variations and metabolite 
production, and furthermore to investigate the interindividual variations in cognitive recovery 
after ambulatory surgery with propofol anaesthesia. 
 
The specific aims were: 
 
• To study the effect of genetic polymorphism in CYP2B6 on propofol hydroxylation 
capacity in human liver microsomes. 
 
 
• To study the effect of genetic polymorphism in propofol key metabolising enzymes 
CYP2B6 and UGT1A9,  age and gender on the production of propfol metabolites in 
vivo after propofol bolus and infusion. 
  
• To assess the cognitive recovery using the PQRS and CFQ cognitive tests during the 
first postoperative week after ambulatory breast cancer surgery comparing propofol 
and desflurane anaesthesia. 
 
• To study the PQRS cognitive, nociceptive and emotional test performance at test re-
test in pre-surgery breast cancer patients compared to controls.  
 
  
 14 
MATERIALS AND METHODS 
ETHICAL CONSIDERATIONS 
All studies were approved by the local ethical committee in Stockholm. All the participants in 
the studies signed an informed consent and were informed of the possibility to leave the study 
at any time point. 
PAPER I-II 
Livers 
For the in vitro part of paper I, livers from earlier established liver banks at Karolinska 
Institutet were used. The liver banks were approved by the Regional Ethical Committee. In 
the study, liver material from 68 different livers were used, 32 from men, 34 from women 
and 2 from unknown gender. 
Patients 
The patients included in study I and II were scheduled for minor elective orthopaedic hand 
and foot surgery. They had a physical status classified according to American Society of 
Anesthesiologists I-II (ASA I-II). None of the patients had any cardiovascular, kidney or liver 
disease, nor were taking any regular medication. In study I, a total of 105 patients were 
included, 80 women and 25 men between 16 and 76 years of age. In study II, 98 patients 
were included, 53 women and 45 men with a median age of 48 years. 
In vitro study  
Analysis of CYP2B6 content and associated propofol metabolite production was performed 
according to the method described by Court et al130. 100 µg of human liver microsome, 
NADPH and propofol was allowed to react for 10 minutes, and then stopped with 
acetonitrile. The level of CYP2B6 was analysed through Western Blot; the proteins were 
separated through gel electrophoresis, standards of different CYP2B6 concentrations were 
added to each gel. The proteins were transferred onto a membrane, thereafter anti-human anti 
bodies were added as well as goat anti-rabbit IgG with horse radish peroxidate (HRP). An 
enhanced chemoluminiscent kit detected the chemoluminiscent reaction which correlated to 
the amount of CYP2B6, and the levels of CYP2B6 were calculated using Image Gauge V4.0 
software (Fuji film). 
Anaesthesia  
In both paper I and II, the patients had peroperative monitoring with electrocardiography, non 
invasive blood pressure, pulse oximetry and capnography. Before induction of anaesthesia, 8 
mg of betamethasone was given (as a prophylactic antiemetic). In paper I, with an expected 
time of surgery of 15-20 minutes, anaesthesia was induced with a bolus dose of propofol until 
Loss Of Verbal Response (LOVR), and alfentanil of 0,4 µg/kg. Anaesthesia was maintained 
with inhalation of sevoflurane and oxygen (FiO2 0.5). Ventilation was spontaneous and 
assisted when necessary. Blood samples were taken before induction, 4, 8, 12, 16 and 20 
minutes after induction.   
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In paper II, with an expected time of surgery of approx. 30 minutes, the induction of 
anaesthesia was performed with alfentanil 2-3 µg/kg and a Target Controlled Infusion (TCI, 
Alaris Marsch model) of propofol with a calculated effect site concentration of 4-5 mg/L.  
The patients were breathing spontaneously through a laryngeal mask a mixture of oxygen and 
air (FiO2 0.4). Blood samples were taken before induction, 10, 17, 21, 25, 40 and up to 90 
minutes after induction.   
Blood samples  
Blood samples were stored at 4°C for a maximum of 4 hours before they were centrifuged. 
After centrifugation, buffy coat (leucocytes) was separated and stored in -20 °C for later 
genetic analysis. Further, plasma was separated, acetonitrile with standard thymol was added 
to stop any ongoing metabolism, and the samples were vortexed and centrifuged. The 
supernatant was either immediately analysed for propofol and its metabolites, or stored in -20 
°C for a maximum of 7 days before analysis. 
Genotyping   
Genetic analysis was performed for the alleles CYP2B6 *4, *5 and *6 in the in vitro study, 
CYP2B6 *1, *4, *5, 6, *7 and *9 and UGT1A9 *3 and -275T>A/-2152 in paper I and 
CYP2B *4, *5, *6, *7, *8, *9, *13, *14 and UGT1A9 *3 and -275T>A/-2152 in paper II.  
Genomic DeoxyRibonucelic Acid (DNA) was separated from the liver microsomes using 
QIAamp Tissue DNA preparation kit (Qiagen) and from the human leucocyte cell using QIA 
amp DNA mini kit (Qiagen). The quality and quantity of the purified DNA was analysed 
using NanoDropUV-Vis spectrophotometer.  
The Single Nucleotide Polymorphisms (SNPs) associated with the various alleles were 
analysed using Polymerase Chain Reaction-restriction Fragment Length Polymorphism 
(PCR-RFLP) for the liver microsomes54. For the genotyping of the human DNA, real-time 
PCR with predesigned Taqman allelic discrimination assay was used (ABI 7000 Sequence 
detection System, Applied Biosystems).  
In short, DNA is denaturated, Taq polymeras binds to predesign primers in the region of the 
SNPs of interest, thereafter new DNA chains are constructed. The reaction is repeated for 
exponential production of DNA. For the real-time PCR, a probe with fluorescence binds to 
the region with the SNP, leading to a fluorescent reaction where the SNP of interest is 
present, making it possible to accurately evaluate incidence of SNPs in the material. 
HPLC analysis  
To analyse the plasma levels of propofol and propofol metabolites; PG, 4-OHP, Q1G and 
Q4G, High-Performance Liquid Chromatography (HPLC) according to the method of Court 
et al130 and Vree et al131 was used. In short, the plasma samples are injected into the HPLC, 
and depending on the polarity of the substances to be analysed and the polarity of the 
stationary (column) and the mobile (solution running through the column) phases in the 
HPLC, the retention time (the time taken to pass the column) varies. After having passed the 
stationary phase, the substances are detected via ultraviolet and fluorescent light at specific 
wavelenghts, and based on how much light is absorbed, the amount of each substance present 
can be calculated. Plasma samples were prepared with internal standards with known HPLC 
retention times, thymol for the analysis of propofol and 4-OHP, and hippuric acid for the 
analysis of propofol- and 4-OHP glucuronides.  
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Statistics    
In order to find the amount of propofol and propofol metabolites present in each sample, the 
Area Under the Curve (AUC) from t=0 to last measurable point at the HPLC plasma 
concentration-time curve, was calculated using the trapezoidal rule (WinNonLin 5.2.1). The 
results were normalised with respect to body weight and propofol dose. 
Statistical analysis was performed with GraphPad Prism 5 (Graphpad Software) and Stata 
11.2 (StataCorp LP). Normality distribution was calculated using Kolomogorov-Smirnov 
test. Spearman’s correlation analysis was used for CYP2B6 protein content in livers and 
liver metabolic activity, and also for association between total dose of propofol with 
continuous variables such as age and weight. Mann Whitney U-test and Kruskal – Wallis 
test were used to study the relation between propofol, its metabolites and genotype and 
gender. Any deviation from the Hardy-Weinberg equilibrium of genotype frequency was 
calculated using Chi square test.  
PAPER III-IV 
Patients and controls    
Paper III: 101 ASA I-II women between 20 and 65 years of age planned for breast surgery 
for suspected cancer were primarily enrolled. Exclusion criteria were cardiovascular, liver or 
renal disease, cognitive or psychiatric disorder or lack in Swedish fluency. The surgery was 
planned within the coming three weeks, expected to last 60-120 minutes and consisted of 
sector resection, partial or total mastectomy. 37 patients were subsequently excluded due to 
various reasons, and in the end 64 patients were participating in the study. Patients were 
divided into age groups; 20-45 years and 46-64 years, and within these groups, patients were 
randomly allocated to get propofol or desflurane as the primary anaesthetic drug. The age 
division was performed to avoid a skew distribution between age and anaesthetic drug. The 
patients were blinded to what anaesthetic was given, but not the research personnel due to 
limited resources. 
Paper IV: 71 subjects were initially included in the study; 33 ASA I-II patients and 38 
healthy controls. One patient and eight controls were excluded before baseline test, mainly 
due to emotional instability, and another patient was lost to follow up. The inclusion criteria 
for the patients were 20-65 years of age and planned for breast surgery for suspected cancer 
within the coming three weeks but at least 10 days away from the inclusion day. The 
controls were in the same age span, all working at Karolinska University hospital, and had 
no planned surgery ahead. The exclusion criteria were the same as in paper III for both 
groups.  
Anaesthesia (paper III)  
All patients had peroperative monitoring with electrocardiography, noninvasive blood 
pressure, pulse oximetry and capnography. The induction of anaesthesia was the same for 
both groups; propofol 2–2.5 mg/kg and alfentanil 0.01–0.15 mg/kg. The airway was 
secured by laryngeal mask placement. Ventilation was spontaneous and assisted when <8 
breaths/min. PostOperative Nausea and Vomiting (PONV) prophylaxis was given in 
accordance to Apfel score72. Anaesthesia was maintained with desflurane inhalation or 
propofol infusion (TCI) in the desflurane- and propofol group, respectively. Bispectral 
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index monitoring (BIS) was used aiming at a level of BIS 40–50. Alfentanil was given 
perioperatively in doses of 5–7 µg/kg when signs of pain. Vital parameters and unexpected 
events were recorded. Emergence time, vital signs, anaesthetic, analgesic and anti-emetic 
drug consumption was recorded peroperatively and during the stay at the Post Anaesthesia 
Care Unit (PACU). Postoperative pain was treated with paracetamol 1 g every six hours, 
celecoxib 200 mg once daily and morphine i.v. 0.02-0.06 mg/kg if needed. 
Assessment of postoperative recovery (paper III, IV) 
The assessment tools used to evaluate the postoperative recovery were a modified version of 
the PQRS (paper III and IV) and the CFQ (paper III). We used the physiological (paper III), 
cognitive, nociceptive (pain and nausea) and emotive (sadness and anxiousness) domains of 
PQRS. 
To be postoperatively recovered according to the PQRS, the postoperative score should reach 
baseline score or better for the nociceptive and emotive domains. For the cognitive domain, 
recovery was set according to the recently revised scoring system allowing for the normal 
variation in cognitive performance shown in healthy volunteers127. Beyond that, Royse et al. 
set a level of “good group recovery” when at least 80 % of the subjects in a group reached 
cognitive recovery. This was the level of “recovery” reached by the volunteer group not 
exposed to any event but merely performing re-tests, thus corresponding to the “healthy 
group normal variation” in cognitive performance. During the preparation of manuscript III, 
and before the article about revised scoring by Royse was published, we were informed of the 
forthcoming revision of the cognitive scoring change through personal communication with 
Royse. We did not know by then that the revised scoring system would also imply that 
individuals with a baseline score equal to or lower than the allowed normal variation should 
be excluded from the cognitive assessment. Thus the exclusion of subjects due to low 
baseline score was not used in paper III. However, in paper IV, the exclusion 
recommendation was applied.  The scoring system for the CFQ implies that the higher score, 
the more cognitively affected. To be cognitively recovered according to the CFQ, 
postoperative score should be more than [baseline score +2] to allow for some normal 
variation in everyday cognitive performance. 
Paper III: The patients performed the baseline PQRS and CFQ at the time of inclusion in the 
study. After surgery and anaesthesia, PQRS was performed at 2, 20 (face to face) and 48 
hours (by phone) postoperatively, and CFQ was performed at 72 hours and 1 week (the 
patient returned the questionnaire by mail). The postoperative results were compared to the 
preoperative results and recovery was judged according to the pre-set definitions.  
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Paper IV: The patients and controls performed baseline PQRS at the time of inclusion (face 
to face), and re-tests at 20 and 48 hours after baseline test (by phone). Assessment was made 
with respect to baseline performance (number of patients excluded due to low baseline score), 
variability in cognitive performance as the change in score between baseline and respective 
re-tests, and also to the proportion fulfilling “recovery” at each re-test. The nociceptive and 
emotional domains of PQRS were assessed with respect to absolute score at each test and 
“recovery” at re-tests. 
Statistics 
Paper III: Differences in recovery between groups were analysed using contingency tables 
with Chi-square test and Fisher´s exact test. Continuous variables such as duration of 
anaesthesia were calculated using a two-tailed T-test. All statistics were performed using 
GraphPad Prism version 6.00. A p-value of < 0.05 was considered as statistically 
significant. 
Paper IV: The number of subject fulfilling the baseline test performance in each group was 
analysed with Chi-square test and Fischer´s exact test. RM ANOVA was used to analyse 
difference in change in absolute cognitive score over time, as well as the difference in 
nociceptive and emotional absolute score. The within-group variation in change in 
nociceptive and emotional score over time was assessed using one-way ANOVA. The 
difference in recovery between groups for both the total cognitive domain and each cognitive 
question, as well as for nociceptive and emotional recovery were analysed with the Cochran 
Mantel Haenszel test. A p< 0.05 was considered significant. Based on the exclusion rate seen 
in other patient studies (up to 28 %), we regarded an exclusion rate of 30 % between patients 
and controls to be significant. With a power of 0.8 and p<0.05, a study size of 27 in each 
group was needed. Statistics were performed with Graphpad Prism version 6.0e Statsoft, La 
Jolla, California, USA and IBM SPSS statistics V20.0 Armonk, NY, USA. 
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SUMMARY OF RESULTS  
PAPER I 
In paper I we investigated the impact of genetic polymorphism in key metabolizing enzymes 
CYP2B6 (in vitro and in vivo) and UGT1A9 (in vivo) on propofol metabolite production after 
propofol bolus. In vitro results showed a 28.5-fold variation in CYP2B6 protein content in 
between liver samples (figure 1a below), with increasing amount of CYP2B6 being 
correlated to increased propofol hydroxylation activity. In addition, the female HLM 
contained more CYP2B6 protein compared to male HLM, however with no correlation to 
increased hydroxylation activity. In the in vivo-study, a 50-fold interindividual variation in 
propofol metabolite production was found (figure 1b below), but with no correlation between 
any genotype and level of metabolite. There was an increased level of all glucuronidated 
propofol metabolites (1.2-2.5-fold) in women compared to men. 
  
Fig.1 Formation of 4-hydroxypropofol (4-OHP) in human liver microsomes (HLM) (a) and area under the time–
plasma concentration curve measured over 20 min (AUC20min) of 4-OHP (b). Bars indicate rate 4-OHP 
formation in HLMs at 5 µM propofol expressed as nmol/ min per mg of microsomal protein (a) and the amount 
in plasma expressed as AUC20min of 4-OHP µg*min*ml-1 (b). Solid lines indicate mean values and grey 
shaded areas indicate 95% confidence intervals (CI). 
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PAPER II 
In paper II we wanted to validate the in vivo result from paper I by using a study population 
more evenly distributed between genders, and also to evaluate the metabolite production 
during more steady-state like conditions by administrating propofol as a short infusion (figure 
S1 below).  
 
Similarly to the results in paper I, we found a considerable variation in propofol metabolites 
produced, but no correlation between genotype and propofol metabolite production. There 
was no difference in propofol concentration between gender, but a greater production of all 
propofol metabolites in women compared to men (1.5-4.8 - fold). A new finding in this study 
compared to study I, was the gender difference in CYP2B6 metabolite 4-hydroxypropofol 
level, where a 4.8 fold increased level of metabolites was observed in women compared to 
men. 
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Fig.1. Sex variability of dose- and weight-adjusted area under the time plasma level curves (nM min/mg/kg) 
measured from 0 min. to the last time-point (AUC). A. Propofol AUC B. UGTA1 metabolism pathway: AUC 
of propofol glucuronide (PG) C. CYP2B6 (CYP2C9) metabolism pathway: AUC 4-hydroxypropofol (OHP) 
D. From OHP, subsequent UGT metabolism pathway: AUC of 4-hydroxypropofol-1-O-b-D-Glucuronide 
(Q1G) and 4-hydroxypropofol-4-O-b-D-Glucuronide (Q4G) 
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PAPER III 
In paper III, the aim was to study the impact of propofol compared to desflurane on variation 
in subjective and objective postoperative cognitive recovery after elective ambulatory 
surgery. Our hypothesis was that possible remains of propofol and its metabolites would 
result in an impaired cognitive recovery in the propofol group compared to the desflurane 
group. The study groups consisted of women only, in order to avoid any impact by gender on 
recovery rate. We found no difference in the postoperative cognitive recovery rate between 
patients receiving propofol and desflurane anaesthesia according to the assessment methods 
used, PQRS and CFQ. We did observe a trend towards higher rate of recovery in the propofol 
group at 48 hours according to the PQRS, however not statistically significant. Notable was 
that in none of the groups, more than approx. 2/3 of the patients considered themselves 
cognitively recovered (CFQ) one week after surgery and anaesthesia. Patients demonstrating 
objective cognitive recovery at 48 hours were often not recovered according to CFQ at 72 
hours and vice versa. There was also variability in the PQRS results with some patients 
performing better during recovery as compared to the preoperative baseline test. The recovery 
rates regarding nociceptive and emotional domains were similar between the groups. 
 
 
 
Fig. 3. Per cent of patients cognitively recovered at 2, 20 and 48 h after desflurane (black bars) or propofol 
(grey bars) anaesthesia according to Postoperative Quality of Recovery Scale (PQRS). The stripe-shaded field 
represents the area of ‘good recovery’ according to Royce et al. (Anesthesiology 2013). There is no 
significant difference between the groups at any time point. 
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Fig.2 Per cent of patients cognitively recovered at 72 h and 1 week after desflurane (black bars) or propofol 
(grey bars) anaesthesia according to the Cognitive Failure Questionnaire (CFQ). The stripe-shaded field 
represents the area of ‘good recovery’, which is extrapolated from Royce et al. (Anesthesiology 2013). There 
is no significant difference between the groups at any time point. 
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PAPER IV 
In paper IV, we aimed to investigate to what extent worry and anxiety due to a recent cancer 
diagnosis and approaching surgery could influence the baseline score and cognitive change in 
score at re-test using the PQRS as a recovery assessment tool. This aim was based on our 
somewhat surprising findings in paper III where some patients performed cognitively better 
postoperatively than preoperatively, which we believed could be caused by a relief that 
surgery was over. We found that women with newly diagnosed malignant disease expressed a 
higher level of anxiety than controls (fig. 4). Cognitive test performance at baseline was 
worse in the patient group, resulting in a significantly higher number of patients compared to 
controls being excluded due to low baseline score. We found no difference in the change in 
cognitive score at test re-test when compared to controls (fig. 2). There was no difference in 
the proportion of patients compared to controls being “recovered” at re-tests (fig. 3). 
 
 
Fig. 2 The mean change in score and standard deviation (SD) for the cognitive questions of PQRS for patients 
(red) and healthy controls (black) from baseline until 48 hours after baseline. The “orientation” test was excluded 
from further analysis since all subjects scored a maximum at all test points. The error bars show ±1 SD. p<0.05 
is considered as significant. PQRS; Postoperative Quality of Recovery Scale 
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Fig. 3 The proportion (%) of patients (n=22) and healthy controls (n=28) “recovered” at 20 and 48 hours after 
baseline test. The stripe-shaded field represents the area considered to be the “good group recovery” (80-100%) 
according to Royse et al. (Anesthesiology 2013). PQRS; Postoperative Quality of Recovery Scale. 
 
 
Fig. 4. The absolute score for the nociceptive (pain, PONV) and emotive (sadness, anxiety) domains of PQRS 
for patients (black bars) and healthy controls (checked bars) at baseline, 20 hours and 48 hours after baseline. p* 
<0.05 is considered significant. PONV; PostOperative Nausea Vomiting, PQRS; Postoperative Quality of 
Recovery Scale 
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DISCUSSION 
In this thesis, we were aiming at investigating possible reasons for and characteristics of the 
interindividual variation in clinical response to propofol. Our hypothesis was that inter-
individual differences in genotype could have an impact on the propofol metabolite 
production, which would lead to variations in residual concentrations of active substances, 
which in turn could delay the neurocognitive recovery. A combination of laboratory and 
clinical studies were performed.  
We started with a pharmacogenetic study in vitro and then proceeded with clinical studies 
combined with pharmacogenetic analysis. However, due to the low expected number of 
individuals with rare genotypes, a clinical study was not found to be feasible. We therefore 
chose to design our later clinical study with a focus on investigating possible variations in 
postoperative cognitive recovery after propofol anaesthesia. Due to our findings in the 
recovery study we also studied the impact of worry and anxiety on cognitive performance in 
pre-surgery cancer patients.  
Propofol has been subjected to various studies investigating pharmacodynamic and 
pharmacokinetic variations, as well as postoperative emergence and general recovery with a 
focus on the first 24 hours. However, to our knowledge only one former study have 
investigated the impact of genotype on the propofol metabolism in humans11. Neither has the 
more protracted recovery beyond postoperative day 1 – 2 with a focus on the neurocognitive 
recovery been extensively studied. 
We found a large difference in propofol metabolite production between individuals, but no 
correlation to genotype. Women showed a higher metabolite production than men. The 
protracted cognitive recovery after propofol and desflurane anaesthesia was similar according 
to PQRS and CFQ, and subjectively not complete one week after surgery. Thus our 
hypothesis that possible residual pharmacological effects of propofol and/or its metabolites 
would delay cognitive recovery in comparison with desflurane was not verified. We did 
however a surprising finding; in both groups several patients showed a considerable 
postoperative improvement in the cognitive test when compared to the baseline results.   
We found that the pre-surgery cancer patients had a lower baseline cognitive test performance 
than controls, resulting in a high number of patients not included in further cognitive testing. 
The patient group also expressed a higher level of anxiety. The groups had a similar test re-
test performance in the PQRS cognitive domain. The emotional stress caused by a severe 
disease and approaching surgery should be taken into account as a confounding factor 
affecting the cognitive performance. 
PROPOFOL AND PHARMACOGENETICS  
It is well known that the pharmacokinetics and pharmacodynamics of propofol is complex 
and vary between individuals12 and seemingly also in between gender70,132. There are most 
likely numerous of reasons for the interindividual variations, and since propofol is 
metabolised by the polymorphic enzymes UGT1A9 and CYP2B6, a genetic variance could 
be one of these reasons.  
In study I, our in vitro results revealed a large variation in propofol hydroxylation capacity 
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between liver samples, with a correlation between the amount of CYP2B6 protein content 
and hydroxylation capacity. We found however, testing for CYP2B6*4, *5 and *6, no 
correlation between hydroxylation capacity and genotype. In the in vivo part of the study, we 
primarily studied the genotypes most associated with increased and decreased activity, 
CYP2B6*4 and CYP2B6*6 respectively (also *1, *5, *7, *9). In study II, CYP2B6*8, *13, 
*14 and *18 were analysed as well, in order to expand the search for correlation between 
metabolic level and genotype. As in the in vitro study, we found a great interindividual 
variation in propofol metabolite production in both study I and II, but no correlation between 
genotype and level of metabolites.  
It is important to consider the expected frequency of the particular allele in the population to 
be studied. Our study population consisted of mainly Caucasians. CYP2B6*4 is generally a 
rare allele in the world, and existing in only 2-4 % in the Caucasian population, while 
CYP2B6*6 on the other hand is relatively common, found in around 25 % of Caucasians133. 
For UGT1A9 the expected frequency is around 6% for -275/215256 and 4 % for UGT1A9*3. 
The observed number of alleles in our studies was within Hardy Weinbergs equilibrium, 
meaning they occurred within the expected frequency in the studied population. Still, the 
number of individuals with the alleles was small, and a larger study population would have 
been desirable. 
Another circumstance to consider is a possible substrate depending activity of the enzyme. 
For example, CYP2B6*4 has demonstrated increased activity when exposed to buproprion, 
but decreased activity when exposed to cyclophosphamide133, and a substrate specific activity 
is true for other CYP2B6 alleles as well134. It is thinkable that with propfol as a substrate, 
CYP2B6 and UGT1A9 enzyme activity in vivo do not have the same activity as in vitro. 
Further, other substances may affect the activity of the enzymes. Antidepressants are well 
known inhibitors of CYP2B6135 and oestrogens have been shown to increase CYP2B6 
expression and activity136,137. However, in our studies I and II, the patients were on no regular 
medication, which implies that the risk of unknown substances affecting the propofol 
metabolizing enzymes was probably relatively small.  
In study I, we investigated the metabolite production during the first 20 minutes after 
propofol bolus to picture the activity of the main propofol degrading enzymes. We did not 
aim at fully describing propofol metabolism which would have demanded a different study 
set up with continuous prolonged propofol infusion and a more extensive postoperative blood 
and urine sampling in order to assess the clearance of the drug. During the first phase after 
bolus, we detected a peak and thereafter a quickly decreasing propofol concentration 
(distribution138) and rising propofol metabolite levels which did not completely reach a 
plateau during the time of the study. It can be discussed to what extents the metabolic profile 
during the first 20 minutes after bolus dose reflects the relationship between metabolism and 
genotype. The metabolism mainly takes place in the liver and liver metabolism is dependent 
up on liver blood flow. Liver blood flow in turn is affected by anaesthesia and the circulatory 
changes occurring during anaesthesia induction. The liver blood flow during propofol 
anaesthesia has shown both to remain unaltered and increase30,31,139. In study I and II, the 
peroperative hemodynamic parameters were stable and similar between all patients and 
therefore significant differences in liver blood flow affecting metabolism between individuals 
are not likely ta have occured. We studied ASA I-II patients only and thus we do not expect 
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but cannot exclude any impaired liver function, Also, propofol has not been shown to 
accumulate in patients with liver disease23.   
Propofol is highly protein bound32, and the role of plasma protein level on free propofol 
concentration in plasma and clearance of propofol has shown divergent results140-142. We did 
not measure serum albumin is study I or II, but it is not likely that any of the patients had 
hypoalbuminemia to the point that it would result in an altered pharmacokinetics of propofol. 
As a complement to propofol, the patients were given alfentanil. Propfol slows down the 
clearance of alfentanil and vice versa143-145. The reasons for these pharmacokinetic changes 
are mainly believed to be hemodynamical. All patients in study I and II received a weight-
adjusted dose of alfentanil and were hemodynamically stable, and thus it is not likely that 
differences in propofol pharmacokinetics was caused by any opioid interaction or 
hemodynamic alterations. 
In order to create a more steady state like condition, the patients in study II were receiving a 
Target Controlled Infusion (TCI) of propofol146. The duration of infusion may be considered 
short, but 20 minutes have shown to be enough to reach pseudo steady state11,147,148. Median 
time of infusion during study II was 21 minutes.  
Iohom et al, using similar lengths of propofol infusion, did not find any correlation between 
induction time, propofol requirement, apparent clearance, and CYP2B6*5, *7 and variants of 
the GABA-receptor GABRE11. Another recent work by Khan et al., was studying the 
correlation between the need of propofol dose until Loss Of Consciousness (LOC), Return Of 
Consciousness (ROC), depth of Anaesthesia, propofol concentration and genotypes including 
variants of CYP2B6, UGT1A9, GABRE. They found no correlation between genotype and 
variation in propofol pharmacokinetics148.  
GENDER ASPECTS 
In the in vitro part of study I, a higher CYP2B6 protein expression in the female compared to 
male HLM was observed, but no correlation between the increased CYP2B6 expression and 
propofol hydroxylation capacity. In the in vivo part, there was no correlation between age and 
metabolic profile, but as for gender, women had a significantly higher metabolite 
concentration in plasma for all the UGT1A9 metabolites, but not for the CYP2B6 metabolites 
or propofol concentration. In study II, with a more even gender distribution than in study I, 
there were similar results with higher level for all UGT1A9 metabolites and this time also 
CYP2B6 metabolites in women compared to men.  
Has the measured higher metabolite level in women compared to men during the first 20 
minutes after propofol bolus and infusion a clinical significance? There are numerous of 
differences between men and women, which affect the pharmacokinetics and 
pharmacodynamics of many commonly used drugs70,73. Several of these factors could 
possibly contribute to the gender differences seen with propofol. 
Concerning the gender differences in CYP450 pharmacogenetics, an increased CYP3A4 
activity is observed in women66,149. As for CYP2B6, Lamba et al. found both higher CYP2B6 
expression and activity in women HLM67 but this gender difference could not be shown in 
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vivo68,150.  Female sex hormone oestrogene have shown to increase the CYP2B6 activity, 
however it is not known if this increase would affect the metabolism of propofol137. 
The fact that women wake up faster than men despite the same anaesthetic regime79,80, and 
that a faster decrease in plasma propofol concentration has been observed in women77 could 
be explained by a larger volume of distribution due to a higher percentage of body fat. A 
similar plasma concentration of propofol resulting in deeper level of anaesthesia observed in 
men compared to women according to narcotrend, could be due to difference in sensitivity to 
propofol, in that case an increased propofol sensitivity in men151 which is observed in several 
studies78,152. This finding however is somewhat contradicted by the fact that the female sex 
hormone progesterone with GABA-like properties decreases the need for propofol153. The 
quicker emergence and clearance seen in women could also be explained by a quicker 
metabolism of propofol. This however is opposed by the results of Favetta et al. who found 
no gender difference in propofol metabolism 24 hours after infusion10. Although not our 
study set-up is not thorough enough to demonstrate increased propofol metabolism in 
women, the finding is new and in line with previous knowledge of gender differences in 
propofol pharmacokinetics and pharmacodynamics.  
PROPOFOL AND POSTOPERATIVE COGNITIVE RECOVERY  
Considering assessment method and study groups 
Assessment of cognitive reocvery is complex. When choosing which assessment methods to 
use, we had to consider when and what to measure. The feasibility of the assessment scales 
was also an important factor to consider since a very extensive and comprehensive 
questionnaire might be “too much” for the patients to complete. The aim of study III was to 
assess early as well as intermediate cognitive recovery and also late cognitive recovery up to 
one week after surgery and anaesthesia, with a focus on possible effects on cognitive 
recovery by assumed pharmacological remains of the main anaesthetic. A tool capable of 
objectively evaluating cognitive performance was considered to be the most suitable to 
evaluate possible remaining pharmacological effects on CNS. However, even though 
subjective and objective assessment methods do not usually correspond95, we wanted to 
include a subjective assessment scale since the patient’s self concept of cognitive capacity 
considerably affects functionality in every day life. The well validated and extensively used 
Quality of Recovery 40 (QoR40)154,155 as well as its shorter version QoR 15122, both include a 
broad patient assessment of general recovery. However, since we were focusing on cognitive 
recovery, the CFQ, being a pure cognitive assessment tool was chosen123. 
Since the aim of our study was not POCD, we chose not  to use the extensive test battery used 
for the assessment of Postoperative Cognitive Dysfunction in the POCD studies. Instead we 
used the PQRS cognitive test domain being clinically more feasible. Also, the PQRS would 
allow us to make individual assessments and not only evaluate group recovery rates. 
We used the PQRS cognitive, physiological, nociceptive and emotional domains only 
(leaving out “activities of daily living” and “overall patient perspective”) in order to pinpoint 
our focus area and also to keep the questionnaire feasible.  
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Fig. 4 The figure shows the characteristics of various tools for postoperative assessment of general recovery and 
cognition. The POCD tools are objectively assessing cognition only, while the quality of recovery tools QoR40 
and QoR15 are subjectively assessing general recovery and some cognitive aspects of recovery. The CFQ and a 
the cognitive (objective), physiological, nociceptive and emotional (subjective) domains of PQRS were used in 
study III and IV (marked in red). 
We chose to study a patient group undergoing ambulatory surgery and therefore in need of a 
quick cognitive recovery. Longer surgery and anaesthesia would possibly detect more subtile 
differences in recovery between various anaesthetics, but would also bring more confounding 
factors such as postoperative pain and higher doses of opioids, which may affect cognitive 
recovery.  
To eliminate the effect on recovery by gender differences, we chose to study women only. 
Age is a known risk factor of postoperative cognitive decline4,156, thus we chose the 
maximum age of the study subjects to be 65 years. A relatively healthy study group was 
chosen (ASA I-II) to minimize co-morbidity, which could otherwise also possibly affect 
postoperative recovery156. 
Recovery according to the PQRS 
In study III, we found no difference in postoperative cognitive recovery according to PQRS 
between the propofol or desflurane groups up to 48 hours after surgery and anaesthesia. Nor 
was there any difference in emergency physiological recovery, nociceptive or emotional 
recovery between groups. These are results in line with previous observations with no or 
small differences in cognitive recovery in early recovery114,116,117. Thus it seems that after 
shorter surgery, cognitive recovery after propofol and inhalative anaesthetics is mainly alike. 
Propofol has been associated with impaired postoperative cognition when compared to 
inhalative anaesthetics, but the type and size of surgery and anaesthesia in those studies are 
not comparable to the circumstances of ambulatory surgery and anaesthesia100,157. 
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In order to observe a clinically significant delay in cognitive recovery caused by reduced 
metabolism, the metabolism during redistribution would have to be slow enough to allow the 
plasma propofol level to reach concentrations high enough to affect the CNS. Using the 
PQRS recovery assessment tool, we did not observe such as an effect. It can be argued that 
we should have measured the propofol concentration and metabolite level of the subjects in 
study III, in order to relate those results to the cognitive recovery. However, regardless of 
those parameters, any possibly existing difference in propofol concentration or metabolite 
levels did not affect the cognitive recovery after ambulatory surgery and anaesthesia in a 
clinically significant way in our material. Whether a different tool would have been able to 
detect minor cognitive effects cannot be stated. The usefulness of a more detailed and 
sophisticated method to find very subtile differences in cognitive recovery between groups 
after ambulatory surgery can be discussed. 
Recovery according to the CFQ 
In study III, we found no difference in the rate of subjective cognitive recovery between the 
propofol or desflurane groups according to CFQ. Recovery rate after one week was 65-71 %, 
suggesting that many of the patients did not experience cognitive recovery at that time. 
Previous studies using CFQ have found cognitive desorientation in a substantial part of 
patients as long as 1-2 months after major surgery158,159, but little or no effect on cognition 
three days after ambulatory surgery123 124. It is expected that recovery after major surgery is 
prolonged compared to post ambulatory surgery. It is plausible that cognitive recovery is 
slower after cancer surgery than after non-cancer surgery, due to maintained worry and 
anxiety.  
There was a lack of correlation between subjective and objective recovery in our study, which 
is in line with other studies160-163. A patient grading recovery tool such as the CFQ (or 
QoR40, QoR15, FRI etc.122,154,164) is effective for the assessment of quality of recovery which 
in turn is of great importance since it may well affect the ability to resume everyday activities 
as much or more than the objective cognitive recovery161.  
Also, a proper comparison between the PQRS and the CFQ assessment methods was not 
possible since the tools were used at different time points; 20 and 48 hours for the PQRS and 
72 hours and 1 week for the CFQ. The reason for the CFQ being relatively postponed was for 
the patients to have time to experience the every-day situations asked for in the questionnaire. 
Also even though we requested the patients to leave out questions including situations they 
had not yet confronted postoperatively, almost all questionnaires were completed. Thus, it is 
plausible that some of the situations were not truly experienced but merely answered. 
COGNITIVE PERFORMANCE AND PQRS 
Aspects on PQRS cognitive baseline performance 
We observed that many patients in both the propofol and desflurane group considerably 
improved their cognitive score at 20 hours postoperatively compared to baseline. The 
improvement was most pronounced for “word recall”. Berman et al. observed impaired 
verbal working memory in pre-treatment cancer patients, and a correlation between impaired 
cognitive performance, high level of worry and altered brain function in magnetic resonance 
imaging (MRI)165. We reasoned that the improved postoperative cognition in study III could 
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be a result of relief and decreased worry after completed surgery, and that the cognitive 
recovery performance of these patients might be a reflection of “pre-and post surgery worry 
and anxiety”, rather than of possible remaining effects of the anaesthetic agent. 
Cognitive impairment in women with breast cancer is commonly observed, and has been 
often been regarded as a consequence of chemotherapy treatment166. However, in several 
studies, impaired objective cognition has been observed before chemo treatment as well, 
suggesting that factors associated with the malignant diagnosis, such as increased anxiety, 
depression and sleeplessness contribute to the cognitive impairment 165,167-169.  
Since the cognitive recovery according to PQRS is dependent on the return to baseline result, 
a reliable baseline score is of great importance when using this scale. A cognitive baseline 
test is recommended to take place at least two weeks before surgery in order to minimize 
influence by preoperative anxiety170, which is commonly seen in patients waiting for both 
major and minor surgery171-173. Due to logistic reasons, we sometimes performed our baseline 
testing as close as one week before surgery, which may have affected the baseline results 
negatively. Our study groups had both a malignant disease and were waiting for surgery, two 
factors known to cause anxiety, worry and with that possibly affected cognition.  
“Normal variation” in cognitive performance 
Royse et al. changed the scoring system of PQRS to allow for the day-to-day normal 
variation in cognitive performance found in healthy individuals. With the new score 
allowance, 80 % of the volunteers were “recovered” in a test re-test situation. Therefore a 
group performing the cognitive domain of PQRS and reaching a recovery rate of 80% 
correspond to the normal variation in cognitive performance seen in healthy volunteers127.  
We hypothesised that anxiety and worry in patients waiting for cancer surgery would affect 
cognitive performance and the “normal variation” in cognitive performance compared to 
healthy volunteers. Lack of observation and awareness of variation in cognitive performance 
is highlighted as a problem in studies on POCD, and thus a source of erroneous 
conclusions94,174. The same erroneous conclusions may be committed in studies on cognitive 
recovery if ignoring the existence of normal variation in cognitive performance between 
subsequent test sessions. To better understand if we had studied cognitive performance and 
recovery influenced by anxiety and worry more than influenced by choice of anaesthetics, we 
performed study IV.  
As the revised PQRS scoring system recommends that patients with a baseline score equal to 
or lower than the allowed tolerance factor for each question is excluded (since they will 
otherwise be recovered at re-test no matter how bad the performance), the number of patients 
compared to controls that would fail to perform a baseline score good enough to be included 
in the test was studied. The exclusion number along with the variation in cognitive 
performance measured as change in score between re-tests over time would give an 
indication of how cognitively affected the patient group would be compared to healthy 
subjects. Moreover, the proportion of patients compared to controls succeeding in fulfilling 
the criteria for “recovery” would indicate a possible difference in variability in cognitive 
performance between the groups. Nociception and emotional domains of PQRS were studied 
in parallell.   
We found that a significantly larger proportion of the patients were excluded due to low 
baseline performance and that the patients expressed higher level of anxiety than controls. 
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The change in score at re-tests was similar between the groups. Exclusion rates of 11-28% 
due to poor baseline test performance are also seen in other patient studies using the cognitive 
domain of PQRS. Interestingly, this large preoperative exclusion rate has not been 
commented on in any of the studies86,87,129. In the desflurane and propofol groups in study III, 
none of the patients were excluded due to low baseline score since this regime was not 
published at the writing of the article. If recalculating the baseline data, five patients in the 
desflurane and four patients in the propofol group would have been excluded due to low 
baseline score. This is a slightly lower proportion than in the patient group but a larger 
proportion than in the control group in study IV. Fig. 5 below shows the baseline score data 
of the subjects in study III and IV, and the number of patients excluded in each question 
according to the revised PQRS. Some patients are excluded in several of the questions.  
 
Fig. 5 The figure shows the median, interquartile range, max and min absolute score for all cognitive questions 
for the patients and controls in in study III (desflurane, propofol) and IV (controls, pre-surgery patients). The 
number of subjects excluded due to low baseline score in each group for each question is presented next to each 
respective box. The score on the Y-axis is the maximum score obtainable for that question. There is no 
maximum score for “word generation”. There is no significant difference in median absolute score between the 
groups. 
Even though the exclusion rate in the desflurane and propofol groups was not significantly 
higher than in the control group, it is striking that five patients in those groups failed to 
answer the “orientation” questions; “what is your name, in which town are you now, when 
were you born” (all patients in study IV scored a maximum in this question). Failing this 
question is most likely a result of stress.  
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Emotional distress before and after cancer surgery 
We compared the nociceptive and emotional absolute scores of all the patient groups in study 
III and IV (“pre-surg. patients”, desflurane and propofol groups) to the absolute score of the 
control group at all time points (Fig. 6). 
 
Fig. 6 The figure above shows the nociceptive (pain, PONV) and emotional (sadness, anxiety) domains of the 
PQRS for all the studied groups in study III and IV.p* <0.05 is considered significant. RM ANOVA is used to 
compare patient groups to control group score. The time on the X-axis is from end of surgery/anaesthesia 
(desflurane, propofol, paper III) and from baseline (pre-surg. patients, controls, paper IV) PONV; PostOperative 
Nausea and Vomiting. 
We found the emotional distress to be generally higher in the patient groups at baseline, but 
that once surgery was performed, only the pre-surgery patients maintained a higher sadness 
and anxiety-level compared to controls. This is an interesting finding; the level of emotional 
distress seems to decrease as a result of completed surgery but is maintained in the non-
operated group of patients. This may be one of the reasons for some patients’ markedly 
improved cognitive performance after surgery in study III. It is conceivable that the high 
sadness and anxiety level contributed to the low baseline score in the pre-surgery patient 
group. It is also thinkable that the large exclusion rate from the cognitive assessment due to 
low baseline cognitive test score observed in the other studies using the PQRS, could be 
partly caused by a high level of preoperative stress and worry. It is not known how large a 
proportion of the patients in other PQRS studies were waiting for cancer surgery, which 
might increase the preoperative anxiety. It is noticeable that the rate of emotional recovery 
tells relatively little about the actual level of anxiety and sadness, since that level may be high 
both pre-and postoperatively and in that case results in a “good recovery” even though the 
patient is emotionally very distressed.  
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The PQRS nociceptive domain 
 “Pain” was as expected significantly higher in the operated groups when compared to 
controls. There was no difference between the groups with regard to PONV, which suggests 
that anti-emetic prophylaxis given according to risk factors results in no increased PONV risk 
after desflurane anaesthesia compared to propofol anaesthesia after shorter breast surgery, 
even though volatile anaesthesia is more prone to provoke nausea and vomiting6,17,72. 
Change in PQRS cognitive score at test re-test 
There was no difference in change in score at test re-test between control and pre-surgery 
patients, and when we compared all groups from study III and IV, the similarity between 
groups remained except for “digits backward“ at 20 hours (propofol vs. controls/pre-surgery 
patients).  
 
The figure shows the combined results of mean change in score and standard deviation from baseline to 
respective measurement point for each cognitive question (not orientation due to maximum score for both groups 
in study IV) of the PQRS from paper III (desflurane and propofoI) and paper IV (pre-surg. patients and controls) 
at 20 h and 48 h after anaesthesia/surgery (paper III) or baseline test (paper IV). *p< 0.05 at “digits backward” 
20h for controls vs propofol and pre-surg. patients vs. propofol. PQRS; Postoperative Quality of Recovery Scale. 
A small positive change in score as a result of a learning effect is an expected result over time 
in cognitively unaffected subjects in a test re-test situation, with the largest change from the 
first to the second test127. A lack of improvement in score over time is suggested to be 
interpreted as a sign of cognitive impairment94. In both study III and IV, the overall trend is a 
higher score at 48 hours than at baseline. The propofol group had a negative change in score 
at 20 h for “digits backward”, but also the largest positive change in score for “word recall”, 
and cannot be considered more cognitively affected than any other group. There is a trend of 
the controls having a smaller SD than the patient groups in all questions, which may be 
interpreted as a more consistent cognitive test performance in that group. The difference is 
merely a trend.  
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Fulfil l ing the PQRS “recovery” criteria 
To study to what extent malignancy, surgery and anaesthesia seemed to affect the ability to 
fulfil the cognitive “recovery” criteria of the PQRS, we compared the proportion reaching 
“recovery” between all the patient groups and the controls. 
 
The figure shows the combined results of cognitive recovery according to PQRS from paper III (desflurane and 
propofoI) and paper IV (pre-surg. patients and controls) at 20 h and 48 h after anaesthesia/surgery (paper III) or 
baseline test (paper IV). The stripe-shaded field represents the area of “good recovery” according to Royse et al. 
(Anesthesiology 2013). PQRS; Postoperative Quality of Recovery Scale. 
Interestingly, at 20 hours, the “recovery” rate in the pre-surgery group was similar to the 
newly operated groups, only the healthy control group reached “good recovery” rate of 80%. 
All groups reached “good recovery” at 48 hours except for the desflurane group. The 
differences in “recovery” between groups are relatively small, and should be interpreted 
carefully since several factors beyond our control and knowledge are likely to affect 
recovery127. However, it seems that preoperative stress can affect the abililty to fulfil the 
PQRS “recovery” criteria as much as ambulatory surgery and anaesthesia. 
In general, when studying postoperative cognitive recovery in patients who are likely to be 
influenced by several factors affecting cognition such as severe disease, all factors have to be 
taken into consideration when assessing baseline performance and choosing assessment tool. 
If the study intends to, as in our case, study the effect on cognition of remaining anaesthetics, 
the impact of other factors can overwhelm and even eliminate the effect of what is really 
intended to be studied. If the positive effect on cognitive performance by for example relieve 
that surgery is over, is greater than the possible negative effects of residual anaesthetic 
effects, then the net effect will be a relative improved cognitive performance.  
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CLINICAL IMPLICATIONS AND FUTURE 
PERSPECTIVES 
The postoperative recovery depends on various factors, and those factors vary in between 
patients. The aim for the anaesthetist is to tailor the anaesthesia to each patient. Even though 
most patients receive properly adjusted propofol anaesthesia, some patients may risk being 
underdosaged or receiving an overdose. Knowing when and how to adjust our anaesthesia 
would simplify the adjustment to the individual patient. 
In this thesis, we found no correlation between studied genotypes and propofol metabolite 
concentration in plasma. Since the genotypes seemingly involved in increased and decreased 
propofol metabolism are rare, a considerably larger study including thousands of patients 
would be needed in order to enable any conclusions on correlation between genotype and 
propofol metabolism. The consequences of anaesthetising a fast or a slow metaboliser 
without knowing it may have serious consequences for the individuals affected, even though 
they are few. Awareness is a risk from undertreatment while prolonged recovery, depressed 
breathing and hemodynamic instability are risks of an overdose. The right way to achieve the 
knowledge of how to individualise propofol anaesthesia may not be through clinical patient 
studies since the size of the studies have to be very large in order to find the possible few 
slow and fast individuals. A genetic mapping of individuals is a more realistic way to search 
for the probable outliers. It would also be possible to study the genotype and propofol 
metabolism in patient outliers that either demand very large doses of propofol, or have a 
significantly prolonged recovery after propofol anaesthesia.  
The finding that women had a higher propofol metabolite production in plasma compared to 
men is in line with the many clinical observations of gender difference in response to 
propofol. Women wake up faster than men after propofol anaesthesia, women demand a 
higher propofol dose than men to maintain the same level of anaesthetic depth, and women 
experience awareness more often than men. The reasons for these findings may be 
pharmacokinetical and/or pharmacodynamical. Even though our finding is not conclusive, it 
points out the existing gender differences in response to anaesthetic drugs, of which many are 
not fully explained2,70. A larger study with more extended surgery could further clarify if 
there is really a gender difference in propofol metabolism.  
It has to be carefully considered which recovery assessment tool to use when evaluating 
postoperative cognitive recovery. In our studies, the modified version of PQRS has been 
shown to detect varying levels of worry and anxiousness in a patient population, which may 
be of importance for the general recovery (and cognitive recovery) of the individual. The 
PQRS is one of few tools including objective cognitive tests, which is a great advantage of 
the scale. However, the scale commonly seems to exclude a considerable part of patients 
from cognitive assessment due to low baseline score, and that has to be considered. It may be 
that that the excluded part of patients is the proportion with the highest risk of slow cognitive 
recovery, and in that case in need of particular observation.  
Possible differences in propofol pharmacokinetics and dynamics did not seem to affect the 
cognitive recovery after ambulatory surgery and anaesthesia. Increasing the time and size of 
surgery would increase the risk of confounding factors and the conclusion would be difficult 
to interpret. 
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Maybe future studies should focus more on possible association between anaesthestics, 
postoperative cognitive recovery and neurocognitive side effects including POCD.  Hovens et 
al. emphasise the need to fill the gap between preclinical and clinical perspectives of 
POCD175. The transition between a ”normal cognitive recovery” and a pathological cognitive 
state is delicate and when it occurs is unknown. The “Pinocchio trial” is an ongoing 
investigation of the effect of various anaesthetic regimes including propofol, on the 
development of postoperative delirium (PD), early postoperative cognitive dysfunction (up to 
60 minutes postoperatively) and if delayed postoperative recovery increases risk of 
delirium176. The interim results show that the risk for PD is higher after propofol anaesthesia 
compared to sevoflurane and desflurane (Doronzio A, Eur J of Anaesthesiology, 2013). This 
calls for further studies on propofol and cognitive recovery. 
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CONCLUSIONS 
With this thesis we have investigated genetic and cognitive aspects on variation in response 
to the intravenous anaesthetic propofol. The genetic studies were performed on human liver 
tissue as well as on patient material, and the studies on cognitive recovery were conducted in 
a clinical setting and in comparison with desflurane. The conclusion in detail: 
 
• None of the studied genotypes of CYP2B6 *4,*5 or *6 showed any correlation to 
propofol hydroxylation capacity in human liver microsomes. Female livers expressed 
an increased amount of CYP2B6, but this was not correlated to increased 
hydroxylation capacity of propofol.   
 
 
• There was a considerable interindividual variation of propofol metabolite level in 
plasma but no correlation between metabolite level and any of the studied genotypes 
of CYP2B6 and UGT1A9 after bolus dose or short infusion. Females had a higher 
level of UGT1A9 generated metabolites after propofol bolus dose, and of both 
UGT1A9 and CYP2B6 generated metabolites after short propofol infusion. Age had 
no impact on metabolite level. 
 
• There was no difference in cognitive recovery up to one week postoperatively after 
propofol or desflurane anaesthesia in female patients undergoing ambulatory surgery. 
 
• Women with malignant disease and waiting for surgery performing the cognitive, 
nociceptive and emotional test re-test of the PQRS expressed a higher level of 
anxiety, had a worse cognitive performance at baseline but showed no difference in 
cognitive change in score at re-tests when compared to healthy controls.
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“Everything is going to be fine in the end. If it is not fine, it is not the end.” 
Unknown
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